Rhythm

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrillation or flutter (AF). The study, titled “Multi-Center Validation of an Artificial Intelligence-Enabled ECG Model to Predict 1-Year Risk of Atrial Fibrillation or Fl

Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens

Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic’s commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of technologies GALWAY, Ireland, June 3, 2026 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global…

AccurKardia Granted Patent for AI-Driven ECG Detection of Cardiac Amyloidosis

NEW YORK–(BUSINESS WIRE)– #BetterOutcomes–AccurKardia, Inc., an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced that it has been granted US Patent No. 12,620,488 for the company’s proprietary machine-learning-based system for identifying cardiac amyloidosis from a standard, routinely performed 12-lead ECG. Cardiac amyloidosis is a serious, often fatal heart disease in which abnormal proteins build up in heart tissue, causing the heart muscle to stiffen and even

Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia

LAGUNA HILLS, Calif.–(BUSINESS WIRE)—- $ADGM #ARRHYTHMIA–Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the submission of its Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for the vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (“VT”) in patients with isch

AccurKardia’s AK+ Guard™ Named “Best New ECG Technology Solution” By MedTech Breakthrough

NEW YORK–(BUSINESS WIRE)– #Cardiology–AccurKardia, an innovator in ECG-based diagnostics technology, today announced that AK+ Guard™ has been selected as winner of the “Best New ECG Technology Solution” award in the 10th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health and medical technology market. AI-powered AK+ Guard hyperkale

Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System

LAGUNA HILLS, Calif.–(BUSINESS WIRE)—- $ADGM #Arrhythmia–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported six month results from its FULCRUM-VT Investigational Device Exemption (“IDE”) clinical trial, which will be used to support the Company’s application for Food and Drug Administration (“FDA”) Premarket Approval of the vCLAS Ventricular Ablation System. The results were prese